Generic Makers Increase Estrogen Patch Supply
Manufacturers are ramping up production to meet rising demand for estrogen patches in the United States.
Updated on Oct. 20, 2026 in Women’s Health
Live Poll
Should pharmaceutical companies be required to maintain specific supply levels for essential medications during demand spikes?
Following a significant rise in demand, generic drug manufacturers have increased the supply of estrogen patches in the United States. This surge in volume comes after a period of intense market activity between January 2025 and June 2026.
Why it matters
The increased production follows a February 2026 FDA labeling update that sparked higher patient interest. Manufacturers are reallocating global stocks to address shortages and stabilize the domestic supply chain.
Prescriptions for estrogen patches doubled from 1.8 million to 3.6 million during the 18-month period ending in June 2026. While major generic firms have increased output, compounding entities remain unable to produce these complex delivery systems.
The players
FDA
The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human and veterinary drugs.
Amneal
Amneal Pharmaceuticals is a specialty pharmaceutical company focused on the development, manufacturing, and distribution of generic and specialty drug products.
Sandoz
Sandoz is a global leader in generic medicines and biosimilars that provides affordable healthcare solutions to patients and healthcare systems.
Zydus
Zydus Lifesciences is an innovative global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
Mylan/Viatris
Viatris is a global healthcare company formed through the combination of Mylan and Upjohn that focuses on increasing access to medicines worldwide.
The details
Companies including Amneal, Sandoz, Zydus, and Mylan/Viatris have expanded production capacity to compensate for supply chain constraints. These efforts aim to fulfill higher patient requirements following regulatory updates issued earlier in 2026.
Timeline
January 2025: Analysis period for prescription volume begins.
February 2026: FDA releases updated labeling for estrogen therapy products.
June 2026: Analysis period for prescription volume concludes.
September 2026: FDA identifies and reports increased demand for patches.
The Big Picture
The industry's current supply chain reallocation follows the FDA's 2026 estrogen therapy labeling update, which fundamentally altered market demand patterns. This effort marks a departure from reliance on singular stock sources as firms prioritize domestic supply stability.
Patients may find better availability of estrogen patches at pharmacies as manufacturers increase domestic inventory levels. While production is rising, the continued inability of compounding entities to produce these systems means standard generic options remain the primary source of care.
The takeaway
Patients who previously experienced difficulty filling prescriptions for estrogen patches should consult their pharmacist regarding current stock status. As manufacturers reallocate global supplies, availability is expected to stabilize over the coming months.
Further reading
For additional context on therapeutic trends, visit the Women’s Health section.
Source note: This article includes information reported by Drug Store News.
Live Poll
Should pharmaceutical companies be required to maintain specific supply levels for essential medications during demand spikes?
